Literature DB >> 24322483

A randomized trial of telephone-based motivational interviewing for adolescent chronic headache with medication overuse.

Jack Stevens1, John Hayes, Ann Pakalnis.   

Abstract

INTRODUCTION: Nearly 2% of youths suffer from chronic migraine or chronic tension-type headache (CTTH). A contributing factor in approximately 20%-50% of these youths is medication overuse, which involves taking analgesics three or more times per week for three months. The objective of this study was to test motivational interviewing (MI) as an approach to promote adherence to recommendations regarding not only analgesic overuse but also other aspects of treatment plans.
METHODS: A randomized controlled trial was conducted comparing the experimental condition (standard of care clinic-based treatment with supplemental MI phone calls; N = 24) to a control condition (standard of care clinic-based treatment without these supplemental MI phone calls; N = 23). Four months after enrollment, a research assistant who was blinded to study condition telephoned adolescents inquiring about headache frequency, headache severity, and disability.
RESULTS: Headache frequency was lower in the experimental condition versus control condition for those with relatively lower initial levels of headache frequency. In contrast, we did not find greater improvement in headache severity and disability for the experimental condition relative to the control condition. DISCUSSION: Our findings provided some preliminary, albeit limited, support for MI as an approach to improve outcomes for adolescent medication-overuse headache (MOH).

Entities:  

Keywords:  Adolescent; chronic daily headache; motivational interviewing

Mesh:

Substances:

Year:  2013        PMID: 24322483     DOI: 10.1177/0333102413515336

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  7 in total

Review 1.  Design and Reporting Characteristics of Clinical Trials of Select Chronic and Recurrent Pediatric Pain Conditions: An Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks Systematic Review.

Authors:  Marina R Connolly; Jenna Y Chaudari; Ximeng Yang; Nam Ward; Rachel A Kitt; Rachel S Herrmann; Elliot J Krane; Alyssa A LeBel; Shannon M Smith; Gary A Walco; Steven J Weisman; Dennis C Turk; Robert H Dworkin; Jennifer S Gewandter
Journal:  J Pain       Date:  2018-09-13       Impact factor: 5.820

2.  A Pilot Randomized Controlled Trial to Assess the Impact of Motivational Interviewing on Initiating Behavioral Therapy for Migraine.

Authors:  Mia T Minen; Gabriella Sahyoun; Ariana Gopal; Valeriya Levitan; Elizabeth Pirraglia; Naomi M Simon; Audrey Halpern
Journal:  Headache       Date:  2020-01-24       Impact factor: 5.887

Review 3.  Biofeedback and behavioral treatments: filling some gaps.

Authors:  Frank Andrasik; Licia Grazzi
Journal:  Neurol Sci       Date:  2014-05       Impact factor: 3.307

Review 4.  Enhancing Motivation for Change in the Management of Chronic Painful Conditions: a Review of Recent Literature.

Authors:  Brett Ankawi; Robert D Kerns; Sara N Edmond
Journal:  Curr Pain Headache Rep       Date:  2019-08-06

Review 5.  Consumer Health Information Technology in the Prevention of Substance Abuse: Scoping Review.

Authors:  Apoorva Milind Pradhan; Leah Park; Fadia T Shaya; Joseph Finkelstein
Journal:  J Med Internet Res       Date:  2019-01-30       Impact factor: 5.428

6.  Negative effects of accompanying psychiatric disturbances on functionality among adolescents with chronic migraine.

Authors:  Tugba Uyar Cankay; Mert Besenek
Journal:  BMC Neurol       Date:  2021-03-03       Impact factor: 2.474

7.  FRAMES protocol versus simple advice for medication-overuse headache: a prospective, randomized, controlled clinical trial.

Authors:  Anna Letícia Moraes Alves; Izadora Karina Silva; Pedro Henrique Paula Lemos; Victor Lomachinsky Torres; Eric Crevanzi Arraes; Pedro Augusto Sampaio Rocha-Filho
Journal:  Acta Neurol Belg       Date:  2021-07-23       Impact factor: 2.396

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.